Systemic lupus erythematosus seronegative

Lupus eritematoso sistémico seronegativo

Systemic lupus erythematosus is a multisystem inflammatory disease of multifactorial etiology. 90% of cases are registered in women, usually in childbearing age, although it can also affect children, men and the elderly. It is more frequent in black people. Clinical manifestations, course and prognosis vary and, as a rule, antinuclear antibodies are positive in 99.5% of active cases. 0.5% are not, being called seronegative. The ideal and standardized technique for its detection is immunofluorescence using Hep-2 cells as a substrate. A 1: 160 dilution is diagnostic of this collagen disease. There is no cure and the goal of treatment is to control the symptoms. The most commonly used drugs are corticosteroids, antimalarials and immunosuppressants. Abbreviations: SLE, systemic lupus erythematosus; ANAS, antinuclear antibodies.

1. LES y síndromes relacionados. En: Kelley WN. Tratado de reumatología. Madrid, España: Elsevier; 2006. Vol. 2.

2. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Doménech I. Systemic Lupus Erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine. 1993; 72:113-24.

3. Villalobos R, Rovetto P, Cortés A, Restrepo de Rovetto C. Descripción de casos de nefropatía lúpica diagnosticados por biopsia, en el Hospital Universitario del Valle, Cali, 1995-2000. Colomb Med. 2002: 33(4); 145-48.

4. Bustos PG. Pautas y procedimientos en medicina interna. Lupus Eritematoso Sistémico [monografía en Internet]. Buenos Aires: Portales Médicos; 2008[citado 27 Feb. 2010]. Disponible en: http://www.portalesmedicos.com/publicaciones/articles/915/2/Pautas-y-procedimientos-en-Medicina-Interna.-Lupus-eritematoso-sistemico

5. Fundación Mexicana de Lupus. El papel del laboratorio en el diagnóstico y control del lupus [monografía en Internet]. México: La Fundación; 2000[citado 27 Feb. 2010]. Disponible en: http://www.southmex.com.mx/fmxlupus/www/laboratorio.html

6. Harrison TR. Harrison Principios de medicina interna. México: McGraw- Hill; 2006.

7. Gaviria Jaramillo LM, et al. Características clínicas y serológicas de los pacientes con LES de inicio tardío en una población colombiana. Rev Colomb Reum. 2007: 14(1); 23-31.

8. Fernandez M et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum. 2007 May 15; 57(4):576-84.

9. Kim HA, Chung JW, Park HJ. An antinuclear antibody-negative patient with lupus nephritis. Korean J Intern Med. 2009 Mar; 24(1):76-9.

10. Chan TM. Lupus nephritis: induction therapy. Lupus. 2005; 14; s27- 32.

11. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241-50 .

12. Carballo OG. Control de la calidad en la determinación de anticuerpos antinucleares por inmunofluorescencia indirecta[monografía en Internet]. Buenos Aires: MANLAB, Hospital Carlos G. Durand. Unidad Inmunología; 2007[citado 27 Feb. 2010]. Disponible en: http://www.emanlab.com.ar/pdf/publicaciones/anticuerpos_anti-nucleares.pdf

13. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 2006; 70(8): 1403-12.

14. D’Cruz DP, Houssiau FA. The Euro-Lupus Nephritis Trial: the development of the sequential treatment protocol. Lupus 2009; 18(10); 875-7.

15. Tan ME, Cohen SA, Fries FJ, et al. Upadating the American College of Rheumatology Criteria for the Classification of Systemic Lupus Eryhematosus. Arthritis Rheum 1997; 40:1725.

16. Benseler SM, Silverman ED. Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2007 Aug;33(3):471-98.

17. Lalani TA, Kanne JP, Hatfield GA, Chen P. Imaging findings in systemic lupus erythematosus. Radiographics. 2004 Jul-Aug;24(4):1069-86.

18. Contreras G, et al. Sequential therapies for proliferative lupus nephritis. N vEngl J Med. 2004 Mar 4;350(10):971-80.

19. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus. 2008; 17(5); 426-30.

20. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008 Feb 28;358(9):929-39

21. González Naranjo LA, Vásquez Duque GM, et al. Nefropatía lúpica: presentación clínica, clasificación y tratamiento. Rev. Colomb. Reumatol. 2006 Dic.; 13(4): 307-33.

22. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment for lupus nephritis. Cochrane Database Syst Rev. 2004;(1):CD002922. Review

23. Masood S, Jayne D, Karim Y. Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus. 2009 Feb;18(2):106-15.

24. Quintana López G, Fernández Aldana A, et al. Aplicación clínica de los anticuerpos en lupus eritematoso sistémico. Rev. Colomb. Reumatol.2003 Mar.; 10(1): 32-45.

25. Spronk PE, Limburg PC, Kallenberg CG. Serological markers of disease activity in systemic lupus erythematosus. Lupus.1995 Apr; 4(2):86-94.

26. Feltkamp TEW. Antinuclear antibody determination in a rutine laboratory. Ann Rheum Dis. 1996 October; 55(10): 723–727.

27. Fuente MC, Bovone NS, Eposto MO. Autoanticuerpos detectados por inmunoensayo lineal en pacientes seronegativos por inmunofluorescencia. Acta bioquím. clín. Latinoam. 2004; 38 (4): 495-8.

28. Bertsias G, Aloannis JP, et al. EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2008; 67:195-205.

29. Lupus.org [página en Internet]. Washington: Lupus Foundation of America; c2010 [citado 27 Feb. 2010]. Disponible en: http://www.lupus.org/newsite/index.html

30. Carpio Paniagua Daniel. La biopsia renal: importancia clínica. Cuad. Cir. 2003; 17: 112-114.

31. Kavanaugh A, Tomar R, Reveille J, Solomon D, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch Pathol Lab Med. 2000; 124: 71-81.

32. Sada KE, Makino H. Usefulness of ISN/RPS classification of lupus nephritis. J Korean Med Sci. 2009 Jan;24 Suppl:S7-10